New Genitourinary Syndrome of Menopause Treatments

Introduction

Genitourinary Syndrome of Menopause (GSM), characterized by symptoms like vaginal dryness, burning, and urinary incontinence, affects a majority of postmenopausal women. As new research expands the therapeutic options beyond traditional estrogen, understanding the evidence for emerging treatments becomes essential for informed health decisions.

Photobiomodulation Shows Promise for Incontinence and Dryness

Researchers from Universidade Nove de Julho in Brazil have demonstrated that a non-invasive light therapy can reduce key GSM symptoms. In a randomized, double-blind, placebo-controlled trial of 65 postmenopausal women, those receiving photobiomodulation (PBM) experienced a significant reduction in urinary loss compared to the placebo group.

The protocol involved four weekly sessions where an 808 nm laser was applied externally to eight specific vaginal points. Each point received 4 Joules of energy over 40 seconds. Lead author S.R.D.S. Pereira and colleagues reported improved scores on the International Consultation on Incontinence Questionnaire. Women in the PBM group also noted less vaginal dryness and burning. The mechanism is thought to involve light energy stimulating cellular activity, increasing blood flow, and promoting tissue repair in the vulvovaginal area without the thermal damage associated with other laser therapies.

It is important to note that the study did not find a significant improvement in sexual function or pelvic pressure. These results, published in Climacteric, suggest PBM could become a viable non-hormonal option, particularly for urinary symptoms, but longer-term studies are needed to confirm its durability.

Personalization is Central to Effective GSM Management

A clinical perspective from Mayo Clinic specialists reinforces that successful GSM treatment hinges on a tailored strategy. In Clin Pract., Drs. Jyothi Cyriac and Richa Sood argue that management must move beyond a one-size-fits-all approach.

They outline a decision-making framework based on symptom severity, the patient’s cancer history (particularly breast cancer), and individual preferences for treatment modality. For a woman with mild dryness primarily affecting sexual activity, regular vaginal moisturizers and lubricants may suffice. For moderate to severe symptoms involving pain or urinary changes, low-dose vaginal estrogen—available as creams, tablets, or rings—remains the most effective prescription option. For breast cancer survivors, where estrogen is often contraindicated, the focus shifts to non-hormonal choices like ospemifene (a selective estrogen receptor modulator), vaginal dehydroepiandrosterone (DHEA), and energy-based technologies.

This case-based analysis stresses that patient education is foundational. Many women are unaware that GSM is a chronic, progressive condition that rarely improves without intervention. A proactive discussion can prevent years of unnecessary discomfort and is especially important for those at higher risk, such as women who have experienced surgical menopause.

Integrating New and Established Therapies into Practice

The expanding GSM toolkit allows clinicians and patients to build a layered treatment plan. Hormonal therapies work by directly replenishing estrogen to the vaginal tissues, thickening the epithelium, improving blood flow, and restoring the natural acidic pH and moisture. Newer agents like vaginal DHEA (prasterone) function as a local precursor converted into estrogens and androgens right in the vaginal cells, minimizing systemic absorption.

Non-hormonal medical options include the oral drug ospemifene, which acts like estrogen on vaginal tissue but has an anti-estrogenic effect on breast tissue. Over-the-counter moisturizers (e.g., Replens, Hyalogyn) and lubricants provide symptom relief but do not alter the underlying atrophic physiology.

Energy-based devices, including fractional CO2 or erbium lasers and the newer photobiomodulation studied by Pereira’s team, aim to stimulate collagen production and improve vascularization. While laser therapies have shown benefit, they require more long-term safety data and are typically not covered by insurance. This landscape means that for urinary incontinence, a combination approach might involve PBM alongside pelvic floor physiotherapy, a topic explored in our article on Kegels and electromagnetic stimulation.

Navigating Choices and Starting the Conversation

For women experiencing GSM, the first and most critical step is to seek an evaluation. Symptoms like pain during intercourse, persistent dryness, itching, burning, or increased urinary urgency are not an inevitable part of aging. A healthcare provider can perform a simple exam to confirm the diagnosis and rule out other conditions.

Patients should be prepared to discuss all symptoms openly, including sexual function and bladder changes, to help guide therapy selection. Factors like cost, insurance coverage, frequency of application, and personal comfort with different delivery methods (e.g., cream vs. tablet) all play a role. For sexual dysfunction related to low desire, a discussion about testosterone therapy may be relevant. The goal is to craft a sustainable, effective plan that a woman is comfortable using long-term, as ongoing treatment is usually necessary.

Conclusion

Managing GSM effectively relies on recognizing it as a medical condition with multiple evidence-based solutions. From established vaginal estrogen to emerging therapies like photobiomodulation, treatment can be personalized to relieve symptoms, protect urogenital health, and significantly improve quality of life throughout postmenopause.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42060269/
https://pubmed.ncbi.nlm.nih.gov/41892504/
https://pubmed.ncbi.nlm.nih.gov/41707475/